ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,053Medicare Part D Prescriptions Filled, Including Refills

Rank: 87 out of 324

$607K Total Retail Price of All Prescriptions

Rank: 65 out of 324

424 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
17% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Kansas
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 424 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

13% of this provider’s 424 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

2% of this provider’s 9,184 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Kansas
SIMVASTATIN 811 753 1 1
LEVOTHYROXINE SODIUM 611 579 2 2
LISINOPRIL 343 298 3 3
METFORMIN HCL 300 244 4 9
HYDROCHLOROTHIAZIDE 252 243 5 11
LOSARTAN POTASSIUM 252 243 5 15
AMLODIPINE BESYLATE 248 248 7 4
OMEPRAZOLE 221 211 8 6
CARVEDILOL 221 218 8 22
HYDROCODONE-ACETAMINOPHEN 215 180 S3 10 5
CITALOPRAM HBR 214 211 11 16
ZOLPIDEM TARTRATE 212 195 12 20
TRAMADOL HCL 197 175 13 19
METOPROLOL SUCCINATE 168 164 14 17
CRESTOR 151 139 15 28
ATENOLOL 141 141 16 18
GABAPENTIN 128 120 17 13
FUROSEMIDE 120 117 18 7
WARFARIN SODIUM 108 103 19 10
POTASSIUM CHLORIDE 108 96 19 8
DONEPEZIL HCL 107 107 21 25
ALENDRONATE SODIUM 104 103 22 24
CLOPIDOGREL 95 89 23 38
PRAVASTATIN SODIUM 87 86 24 21
ALLOPURINOL 87 85 24 27
ATORVASTATIN CALCIUM 86 75 26 12
ESTRADIOL 80 77 R 27 98
RAMIPRIL 79 73 28 104
METOPROLOL TARTRATE 77 70 29 14
EVISTA 77 77 29 116
TAMSULOSIN HCL 75 68 31 26
ENALAPRIL MALEATE 75 72 31 57
TRAZODONE HCL 75 62 31 42
DOXYCYCLINE HYCLATE 74 56 34 78
PREDNISONE 72 70 35 36
AZITHROMYCIN 71 67 36 48
GLIMEPIRIDE 70 50 37 37
NEXIUM 61 39 38 33
POLYETHYLENE GLYCOL 3350 60 51 39 49
CYCLOBENZAPRINE HCL 59 53 R 40 51
DIOVAN 57 57 41 56
NAMENDA 55 55 42 31
SPIRIVA 55 54 42 70
VYTORIN 53 35 44 140
CEPHALEXIN 52 50 45 90
FLUTICASONE PROPIONATE 52 50 45 32
PLAVIX 51 48 47 63
OXYCODONE HCL 50 19 S2 48 71
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 10, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.